ARTIFICIAL INTELLIGENCE'S IMPACT ON CONTEMPORARY DRUG RESEARCH AND PHARMACEUTICAL FORMULATION

By

DANIEL XAVIER PRASAD

Sree Krishna College of Pharmacy and Research Centre, Trivandrum, Kerala, India.

https://doi.org/10.26634/jchem.4.1.21156

Date Received: 19/08/2024 *Date Revised: 25/08/2024* *Date Accepted: 02/09/2024*

ABSTRACT

This paper explores the multifaceted role of AI in contemporary drug research, emphasizing its ability to analyze vast datasets, predict molecular interactions, and optimize clinical trials. AI's application extends beyond basic research, influencing preclinical studies, pharmaceutical design, clinical trials, and post-approval activities. It also plays a pivotal role in drug repurposing and the advancement of personalized medicine, where treatments are tailored to individual genetic profiles. By integrating AI into various stages of drug development, the industry has achieved increased efficiency, cost-effectiveness, and accuracy. This paper also highlights the regulatory challenges and opportunities posed by AI, stressing the need for a flexible regulatory framework to balance innovation with patient safety. As AI continues to evolve, its impact on the pharmaceutical industry is expected to grow, driving further advancements in drug research and ultimately leading to improved patient outcomes and a more efficient healthcare system.

Keywords: Artificial Intelligence, Machine Learning, Preclinical Studies, Pharmaceutical Design, Clinical Trials, Post-Approval Activities, FDA, CDER, CBER, CDRH.

INTRODUCTION

The advent of Artificial Intelligence (AI) and Machine Learning (ML) has impacted drug research and pharmaceutical formulation. Artificial Intelligence (AI) and Machine Learning (ML) are branches of computer science, statistics, and engineering that use algorithms or models to perform tasks and exhibit behaviors such as learning, making decisions, and making predictions (Dey et al., 2024; Mak & Pichika, 2019). AI, with its ability to analyze vast datasets and identify patterns, is transforming traditional drug discovery processes, making them more efficient and cost-effective. ML, a subset of AI, further enhances this transformation by enabling predictive modeling, which can significantly accelerate the identification of viable drug candidates and optimize their development (Colombo, 2020; Selvaraj et al., 2021).

In the pharmaceutical sector, AI's role has expanded beyond basic research to encompass various stages of drug development. The integration of AI into these processes is not only streamlining operations but also improving the accuracy and reliability of outcomes. For instance, AI-driven tools are now used to design clinical trials, predict patient responses, and even identify potential adverse effects before a drug reaches the market (Sarkar et al., 2023).

Furthermore, the application of AI in pharmaceutical development is for innovation, such as drug repurposing and personalized medicine. With the power of AI, studies can quickly identify existing drugs that can be repurposed to treat new diseases, a practice that has gained significant attention (Gupta et al., 2021; Mak et al., 2023). Additionally, AI is playing an important role in advancing personalized medicine, where treatments are tailored to individual patients based on their genetic makeup. As AI continues to evolve, its impact on the pharmaceutical industry is expected to grow, driving further advancements in drug research and development, ultimately leading to better patient outcomes and more efficient healthcare systems (Pravalika & Sandeep, 2023).

The Drugs and Cosmetics (Amendment) Bill, 2013 was introduced in the Rajya Sabha on August 29, 2013. The Bill amended the Drugs and Cosmetics Act, 1940, and changed the name of the Act to the Drugs, Cosmetics, and Medical Devices Act, 1940.

The definition of drugs is changed to include:

- New drugs that are not in significant use in India and are not recognized as effective and safe by the Drugs Controller General of India (DCGI).
- Drugs approved by the DCGI for certain claims but are being marketed with modified or new claims.
- A fixed-dose combination of two or more drugs that are individually approved but are being combined for the first time in a fixed or changed ratio.
- All vaccines, recombinant deoxyribonucleic acid (DNA)-derived products, living modified organisms, stem cells, gene therapeutic products, etc., which are intended to be used as drugs.

The present-day use of AI in the pharmaceutical sector is not the first instance of computational approaches being applied for this purpose. Computing has played a critical role for decades: computer-aided drug design dates to the 1970s, and in the early 1980s, the "next industrial revolution" was proclaimed, with pharmaceuticals designed solely by computers. Computerized approaches are also routinely used, for example, for screening compound libraries.

Figure 1 shows industrial computers used in pharmaceutical automation.

1. AI in Pharmaceutical Development and Delivery

Figure 2 shows the applications of AI in pharmaceutical development and delivery.

Figure 1. Industrial Computers Used in Pharmaceutical Automation



Figure 2. Applications of AI in Pharmaceutical Development and Delivery

1.1 Basic Scientific Research

- Pharmaceutical discovery usually relies on basic scientific research or a comprehensive understanding of human disease at the molecular level.
- AI supports various types of scientific research, including formulating and evaluating scientific hypotheses.
- AI is also used in research for pharmaceutical discovery.
- A particular breakthrough was the use of AI to solve the "protein folding problem," the question of how a protein's amino acid sequence dictates its three-dimensional atomic structure.

Figure 3 shows the structures of a protein that were predicted by artificial intelligence (blue) and experimentally determined (green).

1.2 Pharmaceutical Discovery and Design

AI has various uses in pharmaceutical discovery and design (bioinformatics), many of which have been applied. AI can be used to identify potential new targets for pharmaceuticals by analyzing large amounts of biological data, thereby identifying specific biomarkers or mutations related to a disease. This improves the understanding of disease mechanisms, which can then be utilized in the discovery of pharmaceuticals.

AI and big data approaches for developing cancer biomarkers have significantly impacted cancer care. For example, RNA profiling is used in treatment. Molecular biomarkers, such as mutations in the estrogen receptor 1 in breast cancer, are used to predict both treatment outcomes and prognosis.

AI can also be used to repurpose existing medicines (repurposing is a strategy to identify new indications or uses for an approved medicine). For example, during the COVID-19 pandemic, one AI-based company input a few clues about how SARS-CoV-2 acts into its algorithm. The algorithm then searched over 50 million medical journal articles to identify the biological pathways that should be targeted to find an approved pharmaceutical that could be repurposed.

Figure 4 shows the pharmaceutical discovery and design of AI in healthcare.

1.3 Preclinical Studies and Pharmaceutical Development

Researchers are also training machine learning models for use in preclinical studies to predict the properties of a given molecule, such as its binding affinity to a target protein or its toxicity. Preclinical studies have been conducted with animal models to replicate aspects of human disease, though these models cannot



Figure 3. Structures of Protein



Figure 4. Pharmaceutical Discovery and Design of AI in Healthcare

encompass all aspects of the disease. Figure 5 shows the preclinical studies conducted with animal models.

It may become possible to use machine learning models with data from heterogeneous biological systems that are sufficiently relevant (such as organoids or organs-on-a-chip) to gradually replace animal models, achieving comparable or better performance. Figure 6 shows human organoids.

An organ-on-a-chip (OOC) is a multi-channel 3D microfluidic cell culture integrated circuit (chip) that simulates the activities, mechanics, and physiological responses of an entire organ or organ system. Figure 7 shows a body-on-a-chip.

1.4 Clinical Trials and Regulatory Approval

Once developers or researchers are ready to enter a medicine or vaccine into clinical development, AI is used to support or automate various aspects of the process,

Figure 5. Preclinical Studies Conducted with Animal Models



Figure 7. Body on Chip

Figure 6. Human Organoids

including design, recruitment, conduct, and analysis. AI has also been used in filing for regulatory approval. Figure 8 shows various aspects of clinical development.

First, AI is employed by pharmaceutical development professionals and clinical trialists to assist with the design of clinical trials, including decentralized trials that utilize "real-world" data, electronic health records, and medical claims. It aids in predicting trial outcomes, assists in site selection, optimizes dose selection and dosing regimens, helps in selecting clinical endpoints, and improves medication adherence to reduce attrition and increase accuracy. Figure 9 shows the use of electronic medical records.

Secondly, AI is increasingly used to streamline and accelerate patient recruitment by identifying or selecting candidates based on their medical history, demographics, and other data, such as social media content. It has also been employed to identify biomarkers for patient selection. Figure 10 shows clinical trials in India.

Thirdly, AI is utilized in clinical trials for collecting, managing, and analyzing data accumulated from



Figure 8. Various Aspects of Clinical Development

Figure 9. Use of Electronic Medical Records

Figure 10. Clinical Trials in India

various digital health technologies during a specific trial. It can also be applied to the assessment of clinical endpoints, such as safety signals (including real-time monitoring during a trial) and outcomes, from data sources that would otherwise be unanalyzable. AI researchers are exploring the possibility of replacing traditional clinical trials with virtual trials.

Figure 11 shows a scenario where the principal investigator is located remotely and supported by a virtual care team.

Fourthly, AI could be applied to analyzing results, providing more informative insights for drug developers, automating the inclusion of data into statistical analysis tools, and producing the documents, tables, reports, and labels required during the clinical development of a compound. AI is also used in preparing the reports necessary for regulatory approval.

Once a pharmaceutical product has been approved, AI may be used to a limited extent in pharmacovigilance, including the automation of reporting individual case study reports to drug regulatory authorities, such as the US Food and Drug Administration, as shown in Figure 12. AI has also been utilized in this manner by the Medical Products Agency in Sweden.

Pharmaceutical companies have increasingly used AI in various aspects of pharmaceutical manufacturing, including:



Figure 11. Principal Investigator Located Remotely and Supported By Virtual Care Team

Figure 12. US Food and Drug Administration

- Process design (to reduce waste and development time).
- Advanced process control, process monitoring, and fault detection (including the use of computer vision to identify packaging irregularities).
- Trend monitoring, including consumer complaints and reports of manufacturing-related deviations.

Figure 13 shows how AI helps pharmaceutical companies stay competitive.

Pharmaceutical companies are increasingly using AI to manage the supply and distribution of medicines, including monitoring the cold chain for vaccine transport. AI can also be utilized for forecasting demand, monitoring and identifying corruption in the supply chain, and anticipating or detecting shortages and stock-outs. Figure 14 shows the 360-degree visibility of the supply chain.

Figure 13. AI Helps Pharmaceutical Companies Stay Competitive



Figure 14. 360-Degree Visibility of the Supply Chain

2. Public Health Benefits of AI

Identifying and maximizing the public health benefits of AI for the development and delivery of pharmaceutical products in:

- Medicines and vaccines to address unmet needs.
- Making clinical trials more inclusive.
- Strengthening pharmacovigilance.
- Monitoring the procurement, supply, and distribution of medicines in low- and middle-income countries.

3. FDA's Perspective on the Use of AI or ML in Drug Development

The FDA is committed to ensuring that drugs are safe and effective while facilitating innovations in their development. As with any innovation, AI or ML creates opportunities and new and unique challenges. To meet these challenges, the FDA has accelerated its efforts to create an agile regulatory ecosystem that can facilitate innovation while safeguarding public health. Figure 15 shows the importance of agility in healthcare.

Technology is revolutionizing patient care, operational efficiency, and regulatory compliance. From electronic health records (EHR) systems to telemedicine platforms, advancements in technology are reshaping healthcare delivery. With the increasing reliance on software solutions in healthcare, effective development methodologies are crucial. Agile methodology is one such approach. Originally designed for the software industry, it has emerged as a transformative method for healthcare. AI and ML will undoubtedly play critical roles in drug development, and the FDA (Figure 16) plans to develop and adopt a flexible, risk-based regulatory framework that promotes innovation while protecting patient safety.

Figure 15. Importance of Agility in Healthcare

Figure 16. FDA

As part of this effort, the FDA's Center for Drug Evaluation and Research (CDER), in collaboration with the Center for Biologics Evaluation and Research (CBER) and the Center for Devices and Radiological Health (CDRH) (Figure 17), issued an initial discussion paper to engage with a range of stakeholders and explore relevant considerations for the use of AI/ML in the development of drugs and biological products. The agency will continue to solicit feedback as it advances regulatory science in this area.

4. Prosperity of Benefits Integration of AI into Pharmaceutical Processes

The integration of these advanced technologies enhances India's competitive stance by dramatically reducing the time and cost associated with drug discovery and development. Generative AI, with its ability to model and predict molecular interactions at an unprecedented scale, opens up new vistas for novel therapeutics. AI contributes to further reducing the time

Figure 17. FDA's (CDER), (CBER) and (CDRH)

and costs associated with bringing new therapies to market. Figure 18 shows the benefits of infusing AI into pharmaceutical processes.

5. Exscientia Bio Pharma Private Limited

Exscientia, considered a pioneer in the field of AI within the biopharma industry, is an AI-driven precision medicine company committed to discovering, designing, and developing the best possible drugs in the fastest and most effective manner using its AI technology (Figure 19). Founded in 2008 by senior executives from top-tier innovator pharmaceutical companies, Exscientia has two R&D centers in Connecticut (US) and Hyderabad (India) and a state-of-the-art GMP commercial manufacturing site in Visakhapatnam, India.

Conclusion

In conclusion, the integration of Artificial Intelligence (AI) and Machine Learning (ML) into the pharmaceutical industry marks a transformative era in drug discovery and development. By significantly reducing the time and costs associated with bringing new therapies to market, AI is revolutionizing the way pharmaceutical companies approach research and development. AI's ability to analyze vast datasets, predict molecular interactions, and optimize clinical trials has not only enhanced the efficiency of these processes but has also opened the door for drug repurposing and personalized medicine. As the industry continues to embrace these advanced technologies, the potential for groundbreaking innovations in healthcare grows, promising better patient outcomes and more effective treatments. The ongoing evolution of AI in pharmaceuticals underscores the importance of adopting a flexible, risk-based regulatory framework that fosters innovation while ensuring patient safety.



Figure 18. Benefits of Infusing AI into Pharmaceutical Processes

Figure 19. Exscientia Bio Pharma Private Limited

References

[1]. **Colombo, S. (2020).** Applications of artificial intelligence in drug delivery and pharmaceutical development. In *Artificial Intelligence in Healthcare* (pp. 85-116). Academic Press.

https://doi.org/10.1016/B978-0-12-818438-7.00004-6

[2]. **Dey, H., Arya, N., Mathur, H., Chatterjee, N., & Jadon, R. (2024).** Exploring the role of artificial intelligence and machine learning in pharmaceutical formulation design. *International Journal of Newgen Research in Pharmacy & Healthcare* (pp. 30-41).

https://doi.org/10.61554/ijnrph.v2i1.2024.67

[3]. **Gupta, R., Srivastava, D., Sahu, M., Tiwari, S., Ambasta, R. K., & Kumar, P. (2021).** Artificial intelligence to deep learning: Machine intelligence approach for drug discovery. *Molecular Diversity,* 25, 1315-1360.

https://doi.org/10.1007/s11030-021-10217-3

[4]. **Mak, K. K., & Pichika, M. R. (2019).** Artificial intelligence in drug development: Present status and future prospects. *Drug Discovery Today,* 24(3), 773-780.

https://doi.org/10.1016/j.drudis.2018.11.014

[5]. **Mak, K. K., Wong, Y. H., & Pichika, M. R. (2023).** Artificial intelligence in drug discovery and development. *Drug*

Discovery and Evaluation: Safety and Pharmacokinetic Assays, (pp. 1-38).
https://doi.org/10.1007/978-3-030-73317-9_92-1

[6]. Pravalika, T., & Sandeep, K. (2023). Artificial intelligence in pharmaceutical technology and drug delivery design. *World Journal of Pharmaceutical Research,* 12(18), 391-418.

[7]. Sarkar, C., Das, B., Rawat, V. S., Wahlang, J. B., Nongpiur, A., Tiewsoh, I., & Sony, H. T. (2023). Artificial intelligence and machine learning technology driven modern drug discovery and development. *International Journal of Molecular Sciences,* 24(3), 2026.
https://doi.org/10.3390/ijms24032026

[8]. Selvaraj, C., Chandra, I., & Singh, S. K. (2021). Artificial intelligence and machine learning approaches for drug design: Challenges and opportunities for the pharmaceutical industries. *Molecular Diversity* (pp. 1-21).
https://doi.org/10.1007/s11030-021-10326-z

ABOUT THE AUTHORS

Daniel Xavier Prasad Sree Krishna College of Pharmacy and Research Centre, Trivandrum, Kerala, India.